Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. VIRACEPT (mésylate de nelfinavir)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • Warning

    You need to be authenticated to perform this action

    No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

VIRACEPT (mésylate de nelfinavir)

Medicine - Posted on Jul 04 2012 - Updated on Jun 12 2019
Active substance (DCI)
  • mésylate de nelfinavir
history (6)
  • 7/4/12

    VIRACEPT (mésylate de nelfinavir)

    VIRACEPT (mésylate de nelfinavir)
    icône flèche
  • 12/19/07

    VIRACEPT (mésylate de nelfinavir)

    VIRACEPT (mésylate de nelfinavir)
    icône flèche
  • 9/15/04

    VIRACEPT (mésylate de nelfinavir)

    VIRACEPT (mésylate de nelfinavir)
    CAV :
    54321
    icône flèche
  • 10/2/02

    VIRACEPT (mésylate de nelfinavir)

    VIRACEPT (mésylate de nelfinavir)
    icône flèche
  • 2/6/02

    VIRACEPT (mésylate de nelfinavir)

    VIRACEPT (mésylate de nelfinavir)
    CAV :
    54321
    icône flèche
  • 10/17/01

    VIRACEPT (mésylate de nelfinavir)

    VIRACEPT (mésylate de nelfinavir)
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • J05AE04
Manufacturer
Laboratoire ROCHE SAS
Presentation

VIRACEPT 50 mg/g, poudre orale
Flacon de 144 g - (Code CIP : 346 169-3)

VIRACEPT 250 mg, comprimé pelliculé
Flacon de 300 (Code CIP : 357 596-5)

All our publications
    Drug therapy Immunologic deficiency syndromes Paediatrics Sexually transmitted diseases Virus diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
BQZXN1K87sbtuccK